Morgan Stanley Has Lowered Expectations for Contineum Therapeutics (NASDAQ:CTNM) Stock Price
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) had its price objective dropped by Morgan Stanley from $25.00 to $20.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price objective suggests a potential upside of 422.19% from the stock’s previous close. CTNM has […]
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) had its price objective dropped by Morgan Stanley from $25.00 to $20.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price objective suggests a potential upside of 422.19% from the stock’s previous close. CTNM has […]
